RESUMO
BACKGROUND: Abdominoperineal resection is the standard curative surgical technique for locally advanced adenocarcinoma of the lower rectum and squamous cell carcinoma of the anal canal after chemoradiotherapy. However, it requires a definitive abdominal colostomy that modifies the body appearance. OBJECTIVE: The study aim was to evaluate the combination of abdominoperineal resection with perineal colostomy reconstruction and Malone antegrade continence enema. DESIGN: This was a retrospective study. SETTINGS: The study was conducted at the Toulouse Hospital Digestive Surgery Department. PATIENTS: All of the patients with advanced adenocarcinoma or squamous cell carcinoma who underwent abdominoperineal resection with perineal colostomy reconstruction and Malone antegrade continence enema (n = 80) between December 1999 and December 2016 were included. MAIN OUTCOME MEASURES: The main outcome was the 5-year overall survival rate. RESULTS: The 5-year overall survival was 74.89% (95% CI, 62.91%-83.50%), and the median recurrence-free survival was 107.6 months (95% CI, 65.1-198.1 mo). The median follow-up was 91.0 months (95% CI, 70.4-116.6 mo). R0 resection was obtained in 64 patients (80.0%). The median Cleveland Clinic Incontinence Score (to assess the functional outcomes) was 9.0 (interquartile range, 1.0-18.0), and it was lower in patients with advanced adenocarcinoma than with squamous cell carcinoma (7.0 (interquartile range, 2.0-18.0) vs 11.0 (interquartile range, 1.0-17.0); p = 0.01). Eleven patients (13.8%) reported perineal stains during the night, and 19 patients (23.8%) needed drugs to reduce colon motility. The rate of severe complications (Clavien-Dindo >II) was 11.7% (n = 9). Definitive colostomy was performed in 15 patients (18.8%). LIMITATIONS: This retrospective study included a small number of patients from a single center. Moreover, the functional outcome was tested with self-report questionnaires (risk of response bias). CONCLUSIONS: This study suggests that abdominoperineal resection associated with perineal reconstruction by perineal colostomy and Malone antegrade continence enema is safe and may improve patient quality of life. See Video Abstract at http://links.lww.com/DCR/B629. RESULTADOS ONCOLGICOS Y FUNCIONALES DE LA RECONSTRUCCIN PLVIPERINEAL MEDIANTE COLOSTOMA PERINEAL Y PROCEDIMIENTO DE MALONE DESPUS DE LA RESECCIN ABDOMINOPERINEAL: ANTECEDENTES:La resección abdominoperineal es la técnica quirúrgica curativa estándar para el tratamiento del adenocarcinoma localmente avanzado del recto inferior y el carcinoma a células escamosas del canal anal, después de radio-quimioterapia. Sin embargo, requiere una colostomía abdominal definitiva que modifica la apariencia corporal.OBJETIVO:El propósito del presente estudio fue el evaluar la combinación de la resección abdominoperineal con la confección de una colostomía perineal asociada a enemas de continencia anterógrada según Malone.DISEÑO:Estudio retrospectivo.AJUSTES:Servicio de Cirugía Digestiva del Hospital de Toulouse, Francia.PACIENTES:Se incluyeron todos los pacientes con adenocarcinoma avanzado o carcinoma de células escamosas que se sometieron a resección abdominoperineal con la confección de una colostomía perineal asociada a enemas de continencia anterógrada según Malone (n = 80) entre diciembre de 1999 y diciembre de 2016.PRINCIPALES MEDIDAS DE RESULTADO:El principal resultado fue la tasa de sobrevida global a 5 años.RESULTADOS:La sobrevida global a 5 años fue de 74,89% (IC del 95%, 62,91 a 83,50) y la mediana de supervivencia libre de recurrencia fue de 107,6 meses (IC del 95%, 65,1 a 198,1). La mediana de seguimiento fue de 91,0 meses (IC del 95%, 70,4-116,6). La resección R0 se obtuvo en 64 pacientes (80,0%). La mediana de puntuación de la escala de incontinencia de la Cleveland Clinic (para evaluar los resultados funcionales) fue de 9,0 [1,0; 18,0], y fue menor en pacientes con adenocarcinoma avanzado que con carcinoma de células escamosas (7,0 [2,0; 18,0] versus 11,0 [1,0; 17,0]; p = 0,01). Once pacientes (13,8%) refirieron manchado perineal nocurno y 19 pacientes (23,8%) necesitaron fármacos para reducir la motilidad del colon. La tasa de complicaciones graves (Clavien-Dindo > II) fue del 11,7% (n = 9). Se realizó colostomía definitiva en 15 (18,8%) pacientes.LIMITACIONES:Este estudio retrospectivo incluyó un pequeño número de pacientes y de un solo centro. Además, el resultado funcional se probó con cuestionarios de autoinforme (riesgo de sesgo de respuesta).CONCLUSIONES:Este estudio sugiere que la resección abdominoperineal asociada con la confección de una colostomía perineal asociada a enemas de continencia anterógrada según Malone es segura y puede mejorar la calidad de vida de los pacientes. Consulte Video Resumen en http://links.lww.com/DCR/B629.
Assuntos
Adenocarcinoma/cirurgia , Carcinoma de Células Escamosas/cirurgia , Colostomia/efeitos adversos , Períneo/cirurgia , Protectomia/métodos , Adenocarcinoma/diagnóstico , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/radioterapia , Adulto , Idoso , Canal Anal/patologia , Carcinoma de Células Escamosas/diagnóstico , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/reabilitação , Quimiorradioterapia/efeitos adversos , Terapia Combinada/efeitos adversos , Incontinência Fecal/tratamento farmacológico , Incontinência Fecal/epidemiologia , Incontinência Fecal/prevenção & controle , Feminino , Seguimentos , França/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Períneo/patologia , Qualidade de Vida , Procedimentos de Cirurgia Plástica/métodos , Neoplasias Retais/patologia , Estudos Retrospectivos , Autorrelato/estatística & dados numéricos , Taxa de SobrevidaRESUMO
CONTEXTO: La incontinencia urinaria (IU), o trastorno del vaciado vesical, se define como la incapacidad de mantener un control de la micción. Los trastornos del vaciado vesical se dividen en cuatro tipos generalmente, éstos son: IU de urgencia (generalmente asociado al síndrome de vejiga hiperactiva); IU de esfuerzo (pérdida de orina asociado al ejercicio, al toser o estornudar); IU mixta (combinación de las dos previas) y finalmente la IU por rebosamiento o retención urinaria no obstructiva. Las estimaciones de prevalencia de estas afectaciones varían debido a las diferencias en las definiciones, pero se ha reportado hasta un 55% en mujeres adultas. La IU de urgencia y la de esfuerzo son los tipos más frecuentes de IU crónica, con una prevalencia del 31% en mujeres mayores de 75 años y de 24 a 45% en mujeres mayores de 30 años, respectivamente. Tanto los hombres como las mujeres se ven afectados, siendo las mujeres más propensas a experimentar la incontinencia. TECNOLOGÍA: La neuromodulación sacra consiste en un generador de pulsos implantable que suministra impulsos eléctricos controlados. El dispositivo utilizado para conseguir la estimulación cuenta con un generador el cual está conectado a cables que conectan con los nervios sacros, generalmente a nivel de la raíz de S3. Dos componentes externos del dispositivo ayudan a controlar la estimulación eléctrica: um magneto de control es accionado por el paciente para prender y apagar el dispositivo y una consola programadora puede ser utilizada por el médico para ajustar los pulsos del generador. Los pacientes deben poder operar el dispositivo y llevar un diario de evacuaciones. OBJETIVO: El objetivo del presente informe es evaluar la evidencia disponible acerca de la eficacia, seguridad y aspectos relacionados a las políticas de cobertura del uso de neuroestimulación/ neuromodulador em incontinencia fecal y/o urinaria. MÉTODOS: Se realizó una búsqueda en las principales bases de datos bibliográficas, en buscadores genéricos de internet, y financiadores de salud. Se priorizó la inclusión de revisiones sistemáticas (RS), ensayos clínicos controlados aleatorizados (ECAs), evaluaciones de tecnologías sanitarias (ETS), evaluaciones económicas, guías de práctica clínica (GPC) y políticas de cobertura de diferentes sistemas de salud. RESULTADOS: Se incluyeron cinco RS, tres estudios prospectivos no controlados, cinco GPC, una evaluación económica, y 26 informes de políticas de cobertura neuromodulación sacra en incontinencia fecal y/o urinaria. CONCLUSIÓN: Evidencia de moderada calidad sugiere que la terapia con neuromodulación sacra, en comparación con otras alternativas terapéuticas, podría reducir el número de eventos de incontinencia urinaria y mejorar la calidad de vida de adultos que han fallado a otras líneas de tratamiento conservador, estos resultados fueron observados en el corto y mediano plazo. Evidencia de moderada calidad sugiere que la terapia con neuromodulación sacra, en comparación con la estimulación del tibial posterior, podría reducir el número de eventos de incontinencia fecal en adultos que han fallado a otras líneas de tratamiento conservador, estos resultados fueron observados en el corto y mediano plazo. Evidencia de muy baja calidad no permite evaluar la eficacia y seguridad de neuromodulación sacra en pacientes pediátricos con incontinencia fecal. Evidencia de muy baja calidad, proveniente de dos series de casos, no permiten sacar conclusiones acerca de la eficacia y seguridad de la neuroestimulación sacra en pacientes adultos com coexistencia de incontinencia fecal y urinaria. Las guías de práctica clínica que han sido relevadas sobre incontinencia fecal o incontinência urinaria contemplan a la neuromodulación sacra como una alternativa terapéutica en tercera línea de tratamiento. Las políticas de cobertura que han sido relevadas en América Latina no mencionan la cobertura de esta tecnología. Los financiadores públicos de Francia, Australia, Estados Unidos, Reino Unido y los privados de Estados Unidos que han sido relevados brindan cobertura de esta tecnología para las dos indicaciones evaluadas. No se hallaron estudios económicos realizados en Argentina que permitan conocer la costo-efectividad y/o el impacto presupuestario de esta tecnología.
Assuntos
Humanos , Incontinência Urinária/tratamento farmacológico , Estimulação Elétrica Nervosa Transcutânea/instrumentação , Incontinência Fecal/tratamento farmacológico , Avaliação em Saúde , Análise Custo-Benefício/economiaRESUMO
BACKGROUND: Fecal incontinence is a socially and emotionally destructive condition that has a negative impact on personal image, self-confidence, and quality of life. Acupuncture is commonly used to treat chronic conditions, including fecal incontinence. However, no relevant systematic review or meta-analysis has been designed to evaluate the effects of acupuncture on fecal incontinence. METHODS: We will identify relevant randomized controlled trials (RCTs) from the Cochrane Library, Medline, Embase, PubMed, Springer, Web of Science, China National Knowledge Infrastructure, VIP Chinese Science and Technology Journals Database, Wanfang database, and clinical trial registration center from their inception to February 28, 2019. The primary outcome measures will be clinical effective rate, functional outcomes, and quality of life. Data that meets the inclusion criteria will be extracted and analyzed using RevMan V.5.3 software. Two reviewers will evaluate the studies using the Cochrane Collaboration risk of bias tool. Publication bias will be assessed by funnel plots, Egger test, and Begg test using the Stata software. Acupoints characteristics will be analyzed by Traditional Chinese Medicine inheritance support system. RESULTS: This study will analyze the clinical effective rate, functional outcomes, quality of life, daily average number of fecal incontinence, and effective prescriptions of acupuncture for patients with fecal incontinence. CONCLUSION: Our findings will provide evidence for the effectiveness and potential treatment prescriptions of acupuncture for patients with fecal incontinence. PROSPERO REGISTRATION NUMBER: PROSPERO CRD42019119680.
Assuntos
Terapia por Acupuntura/métodos , Incontinência Fecal/terapia , Projetos de Pesquisa , Adaptação Psicológica , Antidiarreicos/administração & dosagem , China , Mineração de Dados , Depressão/epidemiologia , Incontinência Fecal/tratamento farmacológico , Incontinência Fecal/epidemiologia , Humanos , Estilo de Vida , Qualidade da Assistência à Saúde , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
BACKGROUND AND STUDY AIMS: Constipation and fecal incontinence are common problems in neurologically impaired children. This paper aims to give an overview on bowel problems in cerebral palsy children and to suggest a stepwise treatment approach. A pubmed search was performed looking at studies during the past 20 years investigating bowel problems in neurologically disabled children. RESULTS: The search revealed 15 articles. Prevalence and presentation was the subject of 8 papers, confirming the importance of the problem in these children. The other papers studied the results of different treatment modalities. No significant differences between treatment modalities could be demonstrated due to small studied cohorts. Therefore, no specific treatment strategy is currently available. An experienced based stepwise approach is proposed starting with normalization of fiber intake. The evaluation of the colon transit time could help in deciding whether desimpaction and eventually laxatives including both osmotic (lactulose, macrogol) as well as stimulant laxatives might be indicated. Or, in case of fast transit loperamide or psyllium can be tried. Surgery should be a last resort option. CONCLUSION: Studies investigating constipation and continence in neurologically impaired children are scarce, making it difficult to choose for the optimal treatment. A stepwise treatment approach is proposed, measuring the colon transit time to guide treatment choices.
Assuntos
Paralisia Cerebral/epidemiologia , Constipação Intestinal/epidemiologia , Incontinência Fecal/epidemiologia , Antidiarreicos/uso terapêutico , Catárticos/uso terapêutico , Criança , Constipação Intestinal/tratamento farmacológico , Constipação Intestinal/fisiopatologia , Incontinência Fecal/tratamento farmacológico , Incontinência Fecal/fisiopatologia , Fármacos Gastrointestinais/uso terapêutico , Trânsito Gastrointestinal , Humanos , Lactulose/uso terapêutico , Laxantes/uso terapêutico , Loperamida/uso terapêutico , Polietilenoglicóis/uso terapêutico , Prevalência , Psyllium/uso terapêuticoRESUMO
BACKGROUND: Bowel disturbances have been identified as the most important risk factor for fecal incontinence (FI). However, few studies have evaluated the impact of fiber supplementation. Our aim was to assess the correlation between the improvement in stool consistency by fiber supplementation and the changes in urgency and number of FI episodes and in the QoL of patients with FI. METHODS: Eighty-three patients who came to our institution with FI and/or fecal urgency associated with loose stools or diarrhea were prospectively included in the study The intervention included dietary advice and methylcellulose 500 mg every 8 h for 6 weeks. All assessments were carried out at baseline and 6 weeks after the start of the intervention, and included a Bristol Stool Scale, a 3-week bowel diary, the St Mark's score, the Fecal Incontinence Quality of Life scale (FIQL) and a bowel satisfaction score. RESULTS: Sixty-one patients completed the study. At baseline 50 reported episodes of urge incontinence, while 11 did not report FI episodes because they rarely left home to avoid leakage. The Bristol score improved to normal stools in 65.6% of patients after treatment. Bowel diaries showed a statistically significant reduction in the number of bowel movements, urge episodes, urge fecal incontinence episodes and soiling per week. The St Mark's score and the bowel satisfaction score significantly improved after methylcellulose and overall deferment time also increased. FIQL significantly improved in two subdomains (lifestyle, coping/behavior). Thirty-one patients (51.7%) were discharged with methylcellulose as the only treatment. CONCLUSIONS: FI may significantly improve with methylcellulose in selected cases. Assessment of fecal consistency and initial treatment with methylcellulose could be started at primary care level to reduce the need for specialist referral.
Assuntos
Defecação , Diarreia/tratamento farmacológico , Fibras na Dieta/uso terapêutico , Incontinência Fecal/tratamento farmacológico , Metilcelulose/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Tratamento Conservador , Diarreia/complicações , Dieta , Suplementos Nutricionais , Aconselhamento Diretivo , Incontinência Fecal/complicações , Incontinência Fecal/fisiopatologia , Fezes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Qualidade da Assistência à Saúde , Índice de Gravidade de Doença , Adulto JovemRESUMO
BACKGROUND: Fecal incontinence is a devastating condition with few US Food and Drug Administration-approved pharmacologic treatment options. Loperamide and psyllium, both first-line treatments, have different mechanisms of action without any comparative data. OBJECTIVE: The purpose of this study was to examine the effectiveness and tolerability of loperamide compared with psyllium for reducing fecal incontinence. We hypothesized that psyllium fiber supplementation would be more effective than loperamide for reducing fecal incontinence episodes and have fewer adverse effects. DESIGN: We conducted a randomized, double-blind, placebo-controlled crossover trial comparing loperamide (followed by psyllium) with psyllium (followed by loperamide). SETTINGS: Our sites included outpatient clinics within a Veterans Affairs medical center and university affiliate. PATIENTS: Participants included community-dwelling adults (n = 80) with at least 1 fecal incontinent episode on a 7-day bowel diary. INTERVENTION: Participants received either daily loperamide (plus placebo psyllium powder) or psyllium powder (plus loperamide placebo) for 4 weeks. After a 2-week washout, participants crossed over to 4 weeks of alternate treatment. MAIN OUTCOME MEASURES: The primary outcome was the number of fecal incontinence episodes from 7-day bowel diaries. Secondary outcomes included symptom severity, quality of life, and tolerability. RESULTS: Mean age was 60.7 ± 10.1 years; 68% were men. After determining nonsignificant carryover effects, combined analyses showed no differences between the loperamide and psyllium groups for reducing fecal incontinent episodes, symptom severity, or quality of life. Within each group, both loperamide and psyllium reduced fecal incontinent episodes and improved symptom severity and quality of life. Constipation occurred in 29% of participants for loperamide vs 10% for psyllium. LIMITATIONS: Limitations include the washout period length and dropout rate after crossing over to the second intervention. CONCLUSIONS: Both loperamide and psyllium improve fecal incontinence. Loperamide was associated with more adverse effects, especially constipation.
Assuntos
Constipação Intestinal/etiologia , Incontinência Fecal , Loperamida , Psyllium , Qualidade de Vida , Idoso , Antidiarreicos/administração & dosagem , Antidiarreicos/efeitos adversos , Catárticos/administração & dosagem , Catárticos/efeitos adversos , Método Duplo-Cego , Esquema de Medicação , Incontinência Fecal/tratamento farmacológico , Incontinência Fecal/fisiopatologia , Incontinência Fecal/psicologia , Feminino , Humanos , Loperamida/administração & dosagem , Loperamida/efeitos adversos , Masculino , Pessoa de Meia-Idade , Psyllium/administração & dosagem , Psyllium/efeitos adversos , Avaliação de Sintomas , Resultado do TratamentoRESUMO
This is the second of a two-part summary of a National Institutes of Health conference on fecal incontinence (FI) that summarizes current treatments and identifies research priorities. Conservative medical management consisting of patient education, fiber supplements or antidiarrheals, behavioral techniques such as scheduled toileting, and pelvic floor exercises restores continence in up to 25% of patients. Biofeedback, often recommended as first-line treatment after conservative management fails, produces satisfaction with treatment in up to 76% and continence in 55%; however, outcomes depend on the skill of the therapist, and some trials are less favorable. Electrical stimulation of the anal mucosa is ineffective, but continuous electrical pulsing of sacral nerves produces a ≥50% reduction in FI frequency in a median 73% of patients. Tibial nerve electrical stimulation with needle electrodes is promising but remains unproven. Sphincteroplasty produces short-term clinical improvement in a median 67%, but 5-year outcomes are poor. Injecting an inert bulking agent around the anal canal led to ≥50% reductions of FI in up to 53% of patients. Colostomy is used as a last resort because of adverse effects on quality of life. Several new devices are under investigation but not yet approved. FI researchers identify the following priorities for future research: (1) trials comparing the effectiveness, safety, and cost of current therapies; (2) studies addressing barriers to consulting for care; and (3) translational research on regenerative medicine. Unmet patient needs include FI in special populations (e.g., neurological disorders and nursing home residents) and improvements in behavioral treatments.
Assuntos
Biorretroalimentação Psicológica , Terapia por Exercício/métodos , Incontinência Fecal/terapia , Qualidade de Vida , Antidiarreicos/uso terapêutico , Incontinência Fecal/tratamento farmacológico , Humanos , National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) , Estados UnidosRESUMO
Fecal incontinence (FI), the involuntary loss of formed stool, can a social and as well as hygiene problem and is often devastating for patients and their caretakers. Current data, which are probably underestimated, indicate that the occurrence is remarkably high. The etiology of FI is multifactorial; risk factors including advancing age, previous obstetric trauma, diabetes, fecal impaction, stroke, and dementia. The management of FI in the elderly depends on etiologic factors. However, there are many treatment options for sufferers of FI including bulking agents, antidiarrheals, anticholinergics, biofeedback, surgery for sphincter defects, and sphincter bulking devices. The appropriate treatment can be guided by a thorough workup of these patients and result in a significant improvement in quality of life.
Assuntos
Biorretroalimentação Psicológica , Incontinência Fecal/tratamento farmacológico , Incontinência Fecal/fisiopatologia , Idoso , Idoso de 80 Anos ou mais , Antidiarreicos/uso terapêutico , Constipação Intestinal/complicações , Constipação Intestinal/tratamento farmacológico , Defecografia , Diarreia/complicações , Diarreia/tratamento farmacológico , Incontinência Fecal/terapia , Humanos , Laxantes/uso terapêutico , Qualidade de VidaRESUMO
AIM/BACKGROUND: Cholestyramine may improve fecal incontinence, but its use has not been assessed. We report our experience with the use of cholestyramine in the treatment of fecal incontinence. MATERIALS AND METHODS: Twenty-one patients (19 female, mean age 65 years) with fecal incontinence (>/=1 episode/week) received cholestyramine along with biofeedback therapy (group A). Stool frequency, stool consistency (Bristol scale), number of incontinent episodes, satisfaction with bowel function (VAS), and anorectal physiology were assessed at 3 months and at 1 year after treatment. Data were compared with a matched group of 21 incontinent subjects (19 female, mean age 64 years) who received biofeedback alone (group B). RESULTS: At 3 months and at 1 year, group A patients showed decreased stool frequency (p < 0.01), stool consistency (p = 0.001), and number of incontinent episodes (p < 0.04). In contrast, stool frequency (p = 0.8) and stool consistency (0.23) were not different from baseline in group B subjects. In both groups, there was improvement in the satisfaction with bowel function (p < 0.05), anal sphincter pressures (p < 0.05) and ability to retain saline infusion (p < 0.05). Mean dose of cholestyramine used was 3.6 g; 13 subjects (62%) required dose titration, and 7 (33%) subjects reported minor side effects. CONCLUSION: Cholestyramine is safe and useful adjunct for the treatment of diarrhea and fecal incontinence. Most patients require small doses, and dose titration is important. The improvement in stool characteristics favors a drug effect, over and above the benefits of biofeedback therapy.
Assuntos
Antidiarreicos/uso terapêutico , Biorretroalimentação Psicológica , Resina de Colestiramina/uso terapêutico , Incontinência Fecal/tratamento farmacológico , Idoso , Canal Anal/efeitos dos fármacos , Canal Anal/fisiopatologia , Antidiarreicos/efeitos adversos , Resina de Colestiramina/efeitos adversos , Terapia Combinada , Defecação/efeitos dos fármacos , Incontinência Fecal/fisiopatologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Satisfação do Paciente , Pressão , Estudos Prospectivos , Fatores de Tempo , Resultado do TratamentoRESUMO
BACKGROUND: Fecal incontinence is common and can be socially debilitating. Nonoperative management of fecal incontinence includes dietary modification, antidiarrheal medication, and biofeedback. The traditional surgical approach is sphincteroplasty if there is a defect of the external sphincter. Innovative treatment modalities have included sacral nerve stimulation, injectable implants, dynamic graciloplasty, and artificial bowel sphincter. DISCUSSION: This review was designed to assess the various surgical options available for fecal incontinence and critically evaluate the evidence behind these procedures. The algorithm in the surgical treatment of fecal incontinence is shifting. Injectable therapy and sacral nerve stimulation are likely to be the mainstay in future treatment of moderate and severe fecal incontinence, respectively. Sphincteroplasty is limited to a small group of patients with isolated defect of the external sphincter. A stoma, although effective, can be avoided in most cases.
Assuntos
Terapia por Estimulação Elétrica , Incontinência Fecal/cirurgia , Algoritmos , Canal Anal/cirurgia , Antidiarreicos/uso terapêutico , Biorretroalimentação Psicológica , Procedimentos Cirúrgicos do Sistema Digestório , Incontinência Fecal/tratamento farmacológico , Humanos , Próteses e Implantes , Recuperação de Função Fisiológica , Resultado do TratamentoRESUMO
The Malone surgical procedure for antegrade continence enema (ACE) greatly improves the quality of life of many patients with fecal incontinence but has several complications. This report describes a technique of percutaneous endoscopic cecostomy (PEC) which was applied in three children with fecal incontinence secondary to anorectal malformation or spina bifida. Using a pediatric fiberscope, a colonoscopy was done which reached the right colon. An intraoperative ultrasound examination confirmed the position of the cecum just below the layers of the abdominal wall. The cecostomy tube was then percutaneously inserted, imitating the steps of percutaneous endoscopic gastrostomy (PEG) using the pull technique. The preliminary results are very encouraging: there are no procedure-related complications in this small series; all the patients are able to carry out the antegrade enema by themselves; and complete control of defecation has been obtained.
Assuntos
Cecostomia/métodos , Endoscopia , Incontinência Fecal/tratamento farmacológico , Incontinência Fecal/cirurgia , Polietilenoglicóis/administração & dosagem , Tensoativos/administração & dosagem , Adolescente , Criança , Colo , Colonoscopia , Incontinência Fecal/diagnóstico , Feminino , Humanos , Masculino , Irrigação Terapêutica/métodosRESUMO
The evaluation described in this article compared the Therevac SB "mini-enema" with bisacodyl suppositories in the bowel management programs of patients with spinal cord injury (SCI). Of particular interest were (a) determining whether the additional costs of Therevac SB could be justified and (b) identifying the degree of bowel program improvement possible. Fourteen SCI patients were selected from the SCI inpatient unit and the clinic of a Department of Veterans Affairs facility. All patients experienced a delay of at least 45 minutes between insertion of a suppository and the beginning of stool evacuation. Each patient used bisacodyl suppositories for five bowel programs, then Therevac SB for five programs, finally repeating the bisacodyl suppositories for five more programs. Each patient maintained a bowel program log. Ten patients completed the evaluation. Using a MANOVA, the authors found a significant difference between bisacodyl and Therevac SB mean evacuation times for this group. An analysis of direct and indirect costs related to bowel care with the two regimens is also presented.
Assuntos
Bisacodil/uso terapêutico , Catárticos/uso terapêutico , Ácido Dioctil Sulfossuccínico/uso terapêutico , Incontinência Fecal/tratamento farmacológico , Glicerol/uso terapêutico , Traumatismos da Medula Espinal/complicações , Adulto , Idoso , Combinação de Medicamentos , Incontinência Fecal/etiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Supositórios , Fatores de TempoAssuntos
Incontinência Fecal/tratamento farmacológico , Adulto , Idoso , Canal Anal/inervação , Biorretroalimentação Psicológica/instrumentação , Terapia Combinada , Incontinência Fecal/etiologia , Incontinência Fecal/fisiopatologia , Feminino , Humanos , Masculino , Mecanorreceptores/efeitos dos fármacos , Mecanorreceptores/fisiopatologia , Pessoa de Meia-Idade , Músculos/inervação , Parassimpatomiméticos/uso terapêutico , Simpatomiméticos/uso terapêuticoRESUMO
For more than 10 years, the Alfred I. duPont Institute's Spinal Dysfunction Clinic in Wilmington, DE, has helped families and their children with myelomeningocele and neurogenic bowels to establish workable, acceptable, physiologically sound bowel programs. The basic bowel management program at the Alfred I. duPont Institute is described here, as is a program by which a child with a neurogenic bowel can obtain continence. The program is based on the child's developmental level, physiological abilities, and any necessary pharmacologic intervention. The program has enabled approximately 75% of its child patients over age 5 with neurogenic bowel to be continent of stool.
Assuntos
Incontinência Fecal/reabilitação , Meningomielocele/complicações , Criança , Protocolos Clínicos , Enema , Incontinência Fecal/tratamento farmacológico , Incontinência Fecal/enfermagem , Humanos , MasculinoAssuntos
Incontinência Fecal , Atropina/uso terapêutico , Biorretroalimentação Psicológica , Difenoxilato/uso terapêutico , Combinação de Medicamentos/uso terapêutico , Eletromiografia , Incontinência Fecal/diagnóstico , Incontinência Fecal/tratamento farmacológico , Incontinência Fecal/etiologia , Incontinência Fecal/fisiopatologia , Incontinência Fecal/cirurgia , Incontinência Fecal/terapia , Humanos , Loperamida/uso terapêutico , Manometria , Radiografia , Reto/diagnóstico por imagem , Reto/fisiopatologiaRESUMO
37 long-stay geriatric patients were studied. All had 80% transit time (TT) in excess of 6 days. Only an average of 23% of markers were passed by day 6 and 30% of patients still had markers in situ after 2 weeks. Three daily enemas had no effect on TT and three daily enemas together with a laxative for 6 days normalized TT in 40% only. A further 3 weeks of laxatives did not prevent constipation from getting worse. The effectiveness of lactulose and poloxalkol-dihydroxyanthroquinolone, respectively, were the same and better than no treatment.